Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models

Carcinogenesis

Volumn 39, Issue 8, 2018, Pages 1068-1078

  Thomas, Ryan M ^a,b   Gharaibeh, Raad Z ^c   Gauthier, Josee ^c   Beveridge, Mark ^a   Pope, Jillian L ^c   Guijarro, Maria V ^c   Yu, Qin ^c   He, Zhen ^c   Ohland, Christina ^c   Newsome, Rachel ^c   Trevino, Jose ^a   Hughes, Steven J ^a   Reinhard, Mary ^c   Winglee, Kathryn ^d   Fodor, Anthony A ^d   Zajac Kaye, Maria ^c   Jobin, Christian ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b South Georgia Veterans Health System ^*  (United States)

^c University of Florida College of Veterinary Medicine   (United States)

^d University of North Carolina at Charlotte   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; RNA 16S;

ADULT; AGED; ANIMAL; BACTERIUM; CARCINOGENESIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETICS; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; INTESTINE; INTESTINE FLORA; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MOUSE; NONOBESE DIABETIC MOUSE; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL MICROBIOME; GERM-FREE LIFE; HOST MICROBIAL INTERACTIONS; HUMANS; INTESTINES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; RNA, RIBOSOMAL, 16S; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85054976871     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgy073     Document Type: Article

References (50)

1. Hruban, R. H. et al. (2000) Progression model for pancreatic cancer. Clin. Cancer Res., 6, 2969-2972.
2. Iacobuzio-Donahue, C. A. et al. (2012) Genetic basis of pancreas cancer development and progression: insights from whole-exome and wholegenome sequencing. Clin. Cancer Res., 18, 4257-4265.
3. Bailey, P. et al.; Pancreatic Cancer Genome Initiative. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531, 47-52.
4. Brat, D. J. et al. (1998) Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol., 22, 163-169.
5. Hruban, R. H. et al. (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol., 25, 579-586.
6. Zheng, L. et al. (2013) Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology, 144, 1230-1240.
7. Johnson, B. A. 3rd et al. (2017) Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin. Cancer Res., 23, 1656-1669.
8. American Cancer Society. (2017). Cancer Facts & Figures 2017. American Cancer Society, Atlanta. https://www. cancer. org/content/dam/cancerorg/ research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/ 2017/cancer-facts-and-figures-2017. pdf
9. Bosetti, C. et al. (2012) Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann. Oncol., 23, 1880-1888.
10. Duell, E. J. et al. (2012) Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol., 23, 2964-2970.
11. Aune, D. et al. (2012) Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann. Oncol., 23, 843-852.
12. Giardiello, F. M. et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119, 1447-1453.
13. Rebours, V. et al. (2008) Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am. J. Gastroenterol., 103, 111-119.
14. Huttenhower, C. et al. (2014) Inflammatory bowel disease as a model for translating the microbiome. Immunity, 40, 843-854.
15. Iida, N. et al. (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342, 967-970.
16. Kostic, A. D. et al. (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology, 146, 1489-1499.
17. Michaud, D. S. et al. (2013) Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut, 62, 1764-1770.
18. Fan, X. et al. (2018) Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut, 67, 120-127.
19. Ren, Z. et al. (2017) Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 8, 95176-95191.
20. Rath, H. C. et al. (1996) Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/ human beta2 microglobulin transgenic rats. J. Clin. Invest., 98, 945-953.
21. Bruns, C. J. et al. (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia, 1, 50-62.
22. Org, E. et al. (2016) Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes, 7, 313-322.
23. Human Microbiome Project, C. (2012) Structure, function and diversity of the healthy human microbiome. Nature, 486, 207-214.
24. Kovacs, A. et al. (2011) Genotype is a stronger determinant than sex of the mouse gut microbiota. Microb. Ecol., 61, 423-428.
25. Lippert, E. et al. (2009) Gnotobiotic IL-10; NF-kappaB mice develop rapid and severe colitis following Campylobacter jejuni infection. PLoS One, 4, e7413.
26. Hill, R. et al. (2010) PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res., 70, 7114-7124.
27. Bischoff, S. C. et al. (2014) Intestinal permeability-a new target for disease prevention and therapy. BMC Gastroenterol., 14, 189.
28. Madsen, K. L. et al. (1999) Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm. Bowel Dis., 5, 262-270.
29. Sun, X. et al. (2012) Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling. Gastroenterology, 142, 86-95. e5.
30. Morgun, A. et al. (2015) Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut., 64, 1732-1743.
31. Corrales, L. et al. (2017) Innate immune signaling and regulation in cancer immunotherapy. Cell Res., 27, 96-108.
32. Hieken, T. J. et al. (2016) The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Sci. Rep., 6, 30751.
33. Yu, G. et al. (2016) Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol., 17, 163.
34. Grice, E. A. et al. (2011) The skin microbiome. Nat. Rev. Microbiol., 9, 244-253.
35. Pushalkar, S. et al. (2018) The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov., 8, 403-416.
36. Geller, L. T. et al. (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 357, 1156-1160.
37. Panebianco, C. et al. (2017) Engineered resistant-starch (ERS) diet shapes colon microbiota profile in parallel with the retardation of tumor growth in in vitro and in vivo pancreatic cancer models. Nutrients, 9, 331.
38. Ahuja, M. et al. (2017) Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. Cell Metab., 25, 635-646.
39. Cai, J. et al. (2017) Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer. Oncotarget, 8, 74406-74422.
40. Muller, M. W. et al. (2007) Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int. J. Cancer, 121, 2421-2433.
41. Delitto, D. et al. (2015) Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunol. Immunother., 64, 1553-1563.
42. Dansranjavin, T. et al. (2006) E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol. Rep., 15, 1125-1131.
43. Li, X. et al. (2014) Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin. Cancer Res., 20, 6529-6540.
44. Taniguchi, H. et al. (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene, 24, 7946-7952.
45. Sethi, V. et al. (2018) Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology, Apr 7, pii:S0016-5085(18)30411-6. doi:10. 1053/j. gastro. 2018. 04. 001.
46. Karlsson, F. H. et al. (2012) Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun., 3, 1245.
47. Tang, W. H. et al. (2014) The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest., 124, 4204-4211.
48. Berer, K. et al. (2011) Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature, 479, 538-541.
49. Rao, V. P. et al. (2006) Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res., 66, 7395-7400.
50. Lakritz, J. R. et al. (2015) Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget, 6, 9387-9396.